Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Heart failure (HF) is a complex clinical syndrome, with more than half of the cases classified as heart failure with preserved ejection fraction (HFpEF). HFpEF is strongly associated with comorbidities such as hypertension, obesity, diabetes, anemia, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), advanced age, and female gender. Despite its high prevalence, the exact pathogenesis of HFpEF remains poorly understood, leading to limited therapeutic options and poor prognosis. Recently, a novel paradigm has emerged, suggesting that comorbidities drive myocardial dysfunction and remodeling in HFpEF through coronary microvascular inflammation. This review summarizes the molecular mechanisms linking inflammation to coronary microvascular dysfunction (CMD) in HFpEF and discusses current therapeutic strategies targeting these pathways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000548233 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microvascular preservation & cardiomyocyte hyperplasia underlie adaptive right ventricle development in congenital heart disease-pulmonary arterial hypertension.
Am J Physiol Heart Circ Physiol
September 2025
Division of Pediatric Critical Care, Department of Pediatrics, University of California, San Francisco, USA.
Right ventricular (RV) failure is the primary cause of death among patients with pulmonary arterial hypertension (PAH). Patients with congenital heart disease-associated PAH (CHD-PAH) demonstrate improved outcomes compared to patients with other forms of PAH, which is related to the maintenance of an adaptively hypertrophied RV. In an ovine model of CHD-PAH, we aimed to elucidate the cellular, microvascular, and transcriptional adaptations to congenital pressure overload that support RV function.
View Article and Find Full Text PDFEfficacy of sonothrombolysis as an adjunct to primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: a systematic review and meta-analysis.
J Thromb Thrombolysis
September 2025
Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt.
In this review, we aimed to evaluate Sonothrombolysis when combined with primary percutaneous coronary intervention (pPCI) in STEMI patients with regard to improving cardiac function and clinical outcomes. This study primarily assesses short-term efficacy outcomes, while long-term impacts, such as mortality, were not evaluated. Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched four electronic databases (PubMed, Scopus, Cochrane Library, and Web of Science) to identify eligible studies reported up to November 2024.
View Article and Find Full Text PDFValidation of angiography-based FFR in non-culprit vessels of patients presenting with STEMI.
Clin Res Cardiol
September 2025
Department of (Interventional) Cardiology, Thoraxcenter, Erasmus University Medical Center, Room Rg-628, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.
Background: Fractional flow reserve (FFR) for non-culprit lesions (NCLs) in patients with ST-elevation myocardial infarction (STEMI) can be influenced by temporary changes in microvascular resistance. Angiography-derived vessel fractional flow reserve (vFFR) has been tested as a less-invasive alternative.
Aims: The FAST STEMI II study aimed to assess the diagnostic performance of acute-setting vFFR vs.
Ranolazine-Induced Type 1 Brugada Pattern.
JACC Case Rep
September 2025
Cardiovascular Diseases Section, Interdisciplinary Department of Medicine (DIM), University of Bari "Aldo Moro," Bari, Italy.
Background: Brugada syndrome (BrS) is a rare inherited arrhythmia disease carrying a variable risk of sudden cardiac death. Diagnosis requires the type 1 Brugada electrocardiographic pattern, which can either be spontaneous or induced by sodium channel-blocking drugs. Ranolazine is an antianginal drug acting on the late sodium current with emerging antiarrhythmic properties; no information is available on the safety of ranolazine use in patients with BrS.
View Article and Find Full Text PDFMyocardial Infarction With Non-obstructive Coronary Arteries in a Nigerian Middle-Aged Woman: A Case Report.
Cureus
August 2025
Department of Internal Medicine, Babcock University Teaching Hospital, Ilishan-Remo, NGA.
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a group of heterogeneous diseases with different pathological mechanisms. It is often under-recognized because of its diverse differential diagnoses like myocarditis, takotsubo cardiomyopathy, spontaneous coronary artery dissection (SCAD), coronary microvascular dysfunction, vasospasm, coronary erosion, and embolism. Evaluation with multimodality imaging including intravascular coronary imaging and cardiac magnetic resonance is often necessary to determine the underlying etiology and management.
View Article and Find Full Text PDF